Azevan Pharmaceuticals, Inc.

Developing Next Generation for the treatment of Central Nervous Disorders

Stress, Mood, and Behavioral Disorders

Worldwide sales of pharmaceuticals for CNS disorders reached $77 billion in 2007, a 9% increase from 2006. Annual growth projections are in the range of 8% - 10%.

Stress-Related Affective Illness: Anxiety and Depression affect over 20 million Americans each year. Many patients with major depression show elevated levels of vasopressin that decline as illness improves.
Annual market: $20 billion

Menstrual-Related Disorders: Primary Primary Dysmenorrhea, Premenstrual Syndrome (PMS) and Premenstrual Dysphoric Dysmenorrhea (PMDD) are common causes of absenteeism and reduced quality of life in women. Clinical reports show efficacy of vasopressin antagonists for the treatment of pain in dysmenorrhea.
Annual market: $4+ billion

Other indications

Cardiovascular disease affects over 62 million Americans and claims nearly 2,600 lives each day. It is the single most common reason for hospitalization of patients 65 years and older.

Congestive Heart Failure (CHF): Nearly 5 million Americans live with CHF with over 500,000 new cases each year. On average, CHF patients are hospitalized every 11 months at an annual treatment cost of $56 billion in the U.S. alone.
Annual market size: $25 billion

Obesity and Addiction (Cannabinoid receptor)

Azevan Pharmaceuticals, Inc. (Azevan or the Company) is developing novel therapeutics for the treatment of disorders of stress, mood, and behavior. The Company leverages its expertise in behavioral neurobiology with its proprietary chemistry platform targeting G-protein coupled receptors (GPCRs) to create drug candidates. Azevan’s first series of clinical candidates selectively block the effects of arginine vasopressin (AVP), which is involved in the pathophysiology of various conditions including stress-related affective illness and menstrual-related disorders.

The Company recently brought its first candidate, SRX251, through a successful Phase I trial and its second candidate, SRX246, is in preclinical development with human trials expected in late Q3 2008.

The value proposition for Azevan lies in its strong preclinical pipeline, the diverse indications and significant potential markets for selective vasopressin antagonists, and the flexibility of its proprietary chemistry that allows targeting of additional high value G-protein coupled receptors.

Phase I trial for first clinical candidate completed in Q1 2008
Azevan’s library is based on proprietary azetidinone chemistry that can be manipulated to target additional high-value GPCRs
In addition to the V1a antagonists progressing through the clinic, multiple backups with pM to low nM affinity for the V1a receptor have been identified
Lead compounds for the development of CB modulators were identified in eight weeks, demonstrating the flexibility and utility of the proprietary technology
Venture-backed company founded and run by experienced chemists and neurobiologists